Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Annie Guérin
Debbie Goldschmidt
Tania Small
Patrick Gagnon-Sanschagrin
Hela Romdhani
Genevieve Gauthier
Sneha Kelkar
Eric Q. Wu
Polly Niravath
Anand A. Dalal
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
[5] Novartis Pharmaceuticals Corporation,undefined
[6] Analysis Group,undefined
[7] Inc.,undefined
[8] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
CDK4/6 inhibitor; HR+/HER2−; Metastatic breast cancer; Monitoring; Oncology; Post-menopausal;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1251 / 1264
页数：13
相关论文
共 50 条
  • [31] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
  • [32] Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2-Advanced Breast Cancer
    Dalal, Anand A.
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Niravath, Polly
    Small, Tania
    ADVANCES IN THERAPY, 2018, 35 (09) : 1356 - 1367
  • [33] Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
    Deborah Goldschmidt
    Anand A. Dalal
    Hela Romdhani
    Sneha Kelkar
    Annie Guerin
    Genevieve Gauthier
    Eric Q. Wu
    Polly Niravath
    Tania Small
    Advances in Therapy, 2018, 35 : 482 - 493
  • [34] American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
    Kwok-Leung Cheung
    Oncology and Therapy, 2021, 9 : 267 - 272
  • [35] A preponderance of post-menopausal HER2+breast cancer in the Vietnamese population
    Niravath, Polly
    Hilsenbeck, Susan G.
    Bondy, Melissa
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (03)
  • [36] uPA/PAI-1 as a predictive Factor in HR+ and HER2 Breast Cancer
    Wieder, V
    Kaufhold, S.
    Kantelhardt, J. E.
    Thomssen, C.
    Vetter, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (06) : E25 - E25
  • [37] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [38] Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer
    Alam, Rahat
    Reva, Anna
    Edwards, David G.
    Lege, Bree M.
    Munoz-Arcos, Laura S.
    Reduzzi, Carolina
    Singh, Swarnima
    Hao, Xiaoxin
    Wu, Yi-Hsuan
    Tian, Zeru
    Natalee, Laura M.
    Damle, Gargi
    Demircioglu, Deniz
    Wang, Yixian
    Wu, Ling
    Molteni, Elisabetta
    Hasson, Dan
    Lim, Bora
    Gugala, Zbigniew
    Chipuk, Jerry E.
    Lang, Julie E.
    Sparano, Joseph A.
    Cheng, Chonghui
    Cristofanilli, Massimo
    Xiao, Han
    Zhang, Xiang H. -F.
    Bado, Igor L.
    CANCER DISCOVERY, 2025, 15 (04) : 818 - 837
  • [39] Experience with eribulin in HR+/HER2-metastatic breast cancer, including a male
    Munoz Sanchez, Maria del Mar
    Soriano Rodriguez, Maria del Carmen
    Molina Garrido, Maria Jose
    Lopez-Gonzalez, Ana
    Garcia-Palomo, Andres
    Lopez-Gonzalez, Laura
    Plata Fernandez, Maria Yessica
    Luque Caro, Natalia
    Sanchez Rovira, Pedro
    FUTURE ONCOLOGY, 2018, 14 (07) : 5 - 12
  • [40] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2-Breast Cancer
    Kang, Connie
    TARGETED ONCOLOGY, 2024, 19 (02) : 289 - 296
12345